Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Federal Trade Commission
McKinsey
US Army
Boehringer Ingelheim
Chubb

Generated: March 24, 2019

DrugPatentWatch Database Preview

HUMALOG KWIKPEN Drug Profile

« Back to Dashboard

When do Humalog Kwikpen patents expire, and when can generic versions of Humalog Kwikpen launch?

Humalog Kwikpen is a drug marketed by Lilly and Eli Lilly And Co and is included in two NDAs. There are three patents protecting this drug.

This drug has fifty-six patent family members in thirty-one countries.

The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are forty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.

Drug patent expirations by year for HUMALOG KWIKPEN
Pharmacology for HUMALOG KWIKPEN
Ingredient-typeInsulin
Drug ClassInsulin Analog
Medical Subject Heading (MeSH) Categories for HUMALOG KWIKPEN

US Patents and Regulatory Information for HUMALOG KWIKPEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG KWIKPEN insulin lispro recombinant INJECTABLE;INJECTION 020563-003 Sep 6, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for HUMALOG KWIKPEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG KWIKPEN insulin lispro recombinant INJECTABLE;INJECTION 020563-003 Sep 6, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly HUMALOG KWIKPEN insulin lispro recombinant INJECTABLE;INJECTION 020563-003 Sep 6, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747-001 May 26, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for HUMALOG KWIKPEN

Country Patent Number Estimated Expiration
Norway 996131 ➤ Try a Free Trial
Australia 2004266131 ➤ Try a Free Trial
Japan 2002504908 ➤ Try a Free Trial
South Korea 101121317 ➤ Try a Free Trial
Hungary 0002877 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2005018721 ➤ Try a Free Trial
Country Patent Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for HUMALOG KWIKPEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2107069 300596 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
2498802 2017030 Norway ➤ Try a Free Trial PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REG. NO/DATE: EU/1/16/1157 20170125
0885961 SZ 2/2005 Austria ➤ Try a Free Trial PRODUCT NAME: INSULIN GLULISINE
0792290 28/2004 Austria ➤ Try a Free Trial PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON; NAT. REGISTRATION NO/DATE: EU/1/04/278/001-009 20040601; FIRST REGISTRATION: LI 56370 56371 56372 20031110
2107069 C201300035 Spain ➤ Try a Free Trial PRODUCT NAME: INSULINA DEGLUDEC; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF FIRST AUTHORISATION IN EEA: 20130121
2498802 CR 2017 00020 Denmark ➤ Try a Free Trial PRODUCT NAME: INSULIN GLARGINE/LIXISENATID; REG. NO/DATE: EU/1/16/1157/001-004 20170113
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKinsey
Mallinckrodt
UBS
QuintilesIMS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.